ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance
- PMID: 38632244
- PMCID: PMC11024157
- DOI: 10.1038/s41419-024-06647-0
ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance
Abstract
Accumulating evidence demonstrates that the activity regulation of ELK3, a member of the E26 transformation-specific oncogene family, is critical to regulating cell proliferation, migration, and survival in human cancers. However, the molecular mechanisms of how ELK3 induces chemoresistance in prostate cancer (PCa) have not been elucidated. In this study, we found that SPOP and ELK3 are an interacting partner. The interaction between SPOP and ELK3 resulted in increased ELK3 ubiquitination and destruction, assisted by checkpoint kinase-mediated ELK3 phosphorylation. Notably, the modulation of SPOP-mediated ELK3 protein stability affected the c-Fos-induced cell proliferation and invasion of PCa cells. The clinical involvement of the SPOP-ELK3 axis in PCa development was confirmed by an immunohistochemical assay on 123 PCa tissues, with an inverse correlation between increased ELK3 and decreased SPOP being present in ~80% of the specimens. This observation was supported by immunohistochemistry analysis using a SPOP-mutant PCa specimen. Finally, docetaxel treatment induced cell death by activating checkpoint kinase- and SPOP-mediated ELK3 degradation, while SPOP-depleted or SPOP-mutated PCa cells showed cell death resistance. Notably, this observation was correlated with the protein levels of ELK3. Taken together, our study reveals the precise mechanism of SPOP-mediated degradation of ELK3 and provides evidence that SPOP mutations contribute to docetaxel resistance in PCa.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11024157/bin/41419_2024_6647_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11024157/bin/41419_2024_6647_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11024157/bin/41419_2024_6647_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11024157/bin/41419_2024_6647_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11024157/bin/41419_2024_6647_Fig5_HTML.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11024157/bin/41419_2024_6647_Fig6_HTML.gif)
![Fig. 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11024157/bin/41419_2024_6647_Fig7_HTML.gif)
![Fig. 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11024157/bin/41419_2024_6647_Fig8_HTML.gif)
Similar articles
-
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.Mol Cancer. 2019 Nov 26;18(1):170. doi: 10.1186/s12943-019-1096-x. Mol Cancer. 2019. PMID: 31771591 Free PMC article.
-
SPOP mutation induces DNA methylation via stabilizing GLP/G9a.Nat Commun. 2021 Sep 29;12(1):5716. doi: 10.1038/s41467-021-25951-3. Nat Commun. 2021. PMID: 34588438 Free PMC article.
-
SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.Neoplasia. 2021 Oct;23(10):1037-1047. doi: 10.1016/j.neo.2021.08.002. Epub 2021 Sep 10. Neoplasia. 2021. PMID: 34509929 Free PMC article.
-
The emerging role of speckle-type POZ protein (SPOP) in cancer development.Drug Discov Today. 2014 Sep;19(9):1498-502. doi: 10.1016/j.drudis.2014.07.009. Epub 2014 Jul 21. Drug Discov Today. 2014. PMID: 25058385 Free PMC article. Review.
-
The ubiquitin ligase adaptor SPOP in cancer.FEBS J. 2019 Oct;286(20):3946-3958. doi: 10.1111/febs.15056. Epub 2019 Sep 18. FEBS J. 2019. PMID: 31495053 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical